Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(22):1644; doi:10.1093/jnci/dji423
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

In Brief

The first 10% of the full text of this article appears below.

Cervical Cancer Vaccine Found Effective in Clinical Trial

A vaccine designed to protect women from being infected with human papillomavirus (HPV) types 6, 11, 16, and 18 was effective in preventing high-grade cervical precancers and noninvasive cervical cancers in a large, randomized clinical trial, according to a statement from the vaccine's manufacturer Merck. Data from the trial were presented last month at the annual meeting of the Infectious Diseases Society of America.

The vaccine, Gardasil, was designed to . . . [Full Text of this Article]

Patients With Localized Prostate Cancer May Benefit From Short Course of Hormone Therapy

Other Health Problems Explain Some of the Racial Disparity in Breast Cancer Survival

FDA Approves Exemestane for Adjuvant Treatment of Breast Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?